Research Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pillBy Healthcare Propulsion StaffAugust 20, 20260 Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo…
Research Obesity not a ‘zero-sum game’ as patients crave optionality, Novo CEO says: ReutersBy Healthcare Propulsion StaffAugust 13, 20260 Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk CEO Mike…
